Inostics GmbH (Inostics) is engaged in commercializing advances in cancer research and technology development to benefit the cancer patients. Inostics mainly focuses on the detection of genetic changes and mutant DNA. For mutant detection of DNA the BEAMing technology is used (BEAMing stands for Beads, Emulsions, Amplification, and Magnetics). It also provides services for companian diagnostics development. The company is a diagnostics service provider, which provides molecular tools for supporting cancer patient management and also drug development. Inostics expanded its business by obtaining a world-wide exclusive license for detection of PIK3CA mutations from Johns Hopkins University. Inostics is headquartered in Hamburg, Germany.